Oxaliplatin: A review in the era of molecularly targeted therapy

Current Oncology

Volumn 18, Issue 1, 2011, Pages 18-25

  Alcindor, T ^a   Beauger, N ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Chemotherapy; Mechanism of action; Oxaliplatin; Targeted therapy

Indexed keywords

AURORA KINASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CASPASE 3; CETUXIMAB; CISPLATIN; CYTOCHROME C; CYTOTOXIC AGENT; DNA; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; GEMCITABINE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PANITUMUMAB; PROTEASOME INHIBITOR; PROTEIN BAX; RAPAMYCIN; RNA POLYMERASE; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR; VINCA ALKALOID; XALIPRODEN;

ACUTE LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CELL; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DNA ADDUCT; DNA SYNTHESIS INHIBITION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DNA INTERACTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RETENTION; DRUG TISSUE LEVEL; DRUG TRANSFORMATION; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEMOLYTIC ANEMIA; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; MESSENGER RNA SYNTHESIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHYSICAL CHEMISTRY; PROTEIN DNA INTERACTION; STOMACH CANCER; THROMBOCYTOPENIA;

EID: 79751512197     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i1.708     Document Type: Article

References (61)

1. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist 2004;9:8-12.
2. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-71.
3. United States, National Institutes of Health, National Cancer Institute (nci). Home > NCI Drug Dictionary > O > Oxaliplatin [Web resource]. Bethesda, MD: nci; n.d. [Available at: www.cancer.gov/drugdictionary/?CdrID=42374; cited April 1, 2010]
4. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003;66:225-37.
5. Zwelling LA, Anderson T, Kohn KW. DNA -protein and DNA interstrand cross-linking by cis- and trans-platinum(ii) diam-minedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 1979;39:365-9.
6. Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58: 920- 7.
7. Di Francesco A, Ruggiero A, Riccardi R. Cellular and molecular aspects for drugs of the future: oxaliplatin. Cell Mol Life Sci 2002;59:1914-27.
8. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004;91:1931-46.
9. Fischel JL, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5 fuorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 2002;86:1162-8.
10. Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009;1:280-91.
11. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010;29:482-91.
12. Beuvink I, Boulay A, Fumagalli S, et al. The motor inhibitor RAD001 sensitizes tumor cells to DNA -damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120:747- 59.
13. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(iv) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999;59:3968-71.
14. El-Akawi Z, Abu-Hadid M, Perez R, et al. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 1996;105:5-14.
15. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003;39:112-19.
16. Prewett M, Deevi DS, Bassi R, et al. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res 2007;13:7432-40.
17. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-5.
18. Masek V, Anzenbacherova E, Machova M, Brabec V, Anzen-bacher P. Interaction of antitumour platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs 2009;20:305-11.
19. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
20. Pieck AC, Drescher A, Wiesmann KG, et al. Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. Br J Cancer 2008;98:1959-65.
21. Veal GJ, Dias C, Price L, et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clin Cancer Res 2001;7:2205-12.
22. Koutras AK, Makatsoris T, Paliogianni F, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004;67:179-82.
23. Carneiro BA, Kaminer L, Eldibany M, Sreekantaiah C, Kaul K, Locker GY. Oxaliplatin-related acute myelogenous leukemia. Oncologist 2006;11:261-2.
24. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008;34:368-77.
25. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-7.
26. Maindrault-Goebel F, Louvet C, André T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fuorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 6). Eur J Cancer 1999;35:1338-42.
27. Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001;37:2457-63.
28. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res 2006;12:4481-4.
29. Park S, Krishnan A, Lin C Y, Goldstein D, Friedlander M, Kiernan M. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008;15:3081-94.
30. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions. Clin Cancer Res 2004;10:4055-61.
31. Grothey A, Nikcevich DA, Sloan JA, et al. Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: results from a placebo-controlled phase iii trial [abstract 4009]. J Clin Oncol 2008;26:. [Available online at www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32445; cited December 17, 2010]
32. Mir O, Alexandre J, Ropert S, et al. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. Anticancer Drugs 2009;20:105-8.
33. Kuo DYS, Blank S V, Christos PJ, et al. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study. Gynecol Oncol 2010;116:442-6.
34. Cohen SJ, Engstrom PF, Lewis NL, et al. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Am J Clin Oncol 2008;31:1-5.
35. Zafar S, Marcello J, Wheeler J, et al. Treatment-related toxicity and supportive care in metastatic colorectal cancer. J Support Oncol 2010;8:15-20.
36. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000;6:1205-18.
37. Kweekel DM, Gelderblom H, Guchelaar J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;31:90-105.
38. Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol 2002;19:261-5.
39. Takimoto CH, Graham MA, Lockwood G, et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 2007;13:4832-9.
40. Synold TW, Takimoto CH, Doroshow JH, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2007;13:3660-6.
41. Brouwers E, Huitema A, Beijnen J, Schellens J. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008;8:7.
42. Mathé G, Kidani Y, Triana K, et al. A phase i trial of trans-1-diaminocyclohexane oxalato-platinum (l-ohp). Biomed Pharmacother 1986;40:372-6.
43. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303.
44. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase ii studies of oxaliplatin (LOHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fuoropyrimidines. Ann Oncol 1996;7:95-8.
45. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase ii multicentric study. Ann Oncol 1998;9:105-8.
46. Lévi F, Misset JL, Brienza S, Adam R, et al. A chronopharma-cologic phase ii clinical trial with 5-fuorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumour effectiveness against metastatic colorectal cancer. Cancer 1992;69:893-900.
47. de Gramont A, Tournigand C, Louvet C, et al. Oxaliplatin, folinic acid and 5-fuorouracil (FOLFOX) in pretreated patients with metastatic advanced cancer. The GERCOD [French]. Rev Med Interne 1997;18:769-75.
48. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fuorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
49. Cassidy J, Taber nero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
50. Culy CR, Clemett D, Wiseman LR. Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924.
51. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fuorouracil, and leucovorin as adjuvant treatment in stage ii or iii colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
52. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fuorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
53. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19.
54. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
55. Douillard J, Siena S, Cassidy J, et al. Randomized phase 3 study of panitumumab with fo lfo x 4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (MCRC): the prime trial [abstract 10LBA]. Eur J Cancer 2009;7(suppl):6. [Available online at: download.journals.elsevierhealth.com/ pdfs/journals/1359-6349/PIIS1359634909720397.pdf; cited December 24, 2010]
56. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
57. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant MFOLFOX6 with or without cetuxiumab (CMAB) in KRAS wild-type (WT) patients (PTS) with resected stage III colon cancer (CC): results from NCCTG Intergroup phase iii trial N0147 [abstract CRA3507]. J Clin Oncol 2010; 28:. [Available online at www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=41265; cited December 17, 2010]
58. Wolmark N, Yothers G, O'Connell M, et al. A phase iii trial comparing MFOLFOX6 to MFOLFOX6 plus bevacizumab in stage ii or i ii carcinoma of the colon: results of NSABP protocol C-08 [abstract LBA4]. J Clin Oncol 2009;27:. [Available online at www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31978; cited December 17, 2010]
59. Heim M, Scharif M, Zisowsky J, et al. The RAFKINASE inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 2005;16:129-36.
60. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
61. Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/folinic acid/5-fuorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gem-citabine-refractory advanced pancreatic cancer (CONKO003) [abstract 4031]. J Clin Oncol 2005;23:. [Available online at www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID=32322; cited December 17, 2010]